7:50 am Chair’s Opening Remarks

An Overview of Progress Towards Achieving Successful Antigen Specific Therapeutics

8:00 am Antigen-Specific Immunotherapy Approaches for the Treatment of Autoimmune Diseases

  • Emilio Flano Director & Head of Immunology Discovery, Merck & Co

Synopsis

  • Antigen independent and antigen-specific approaches in immunotherapy
  • T cell modulators: approaches for epitope-specific deletion, suppression, or conversion to a regulatory phenotype
  • TCR mimetic antibodies: blocking TCR recognition of an HLA:peptide complex
    and thus T cell activation

8:30 am Translating Innovative Science to Therapies that Establish Immune Tolerance – One Pharma’s Perspective

  • Arpita Maiti Executive Director & Global Head, Global Head Pfizer

Synopsis

  • Overview of how to approach immune tolerance as potential curative therapies for autoimmune diseases through internal efforts and collaboration
  • Leveraging innovative partnership models to access innovation

Clinical Readouts & Translation: What can we Learn from the Clinic? Implications for Designing Clinical Trials

9:00 am Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

  • David Wraith Director of the Institute of Immunology & Immunotherapy , University of Birmingham

Synopsis

  • Review different approaches for induction of antigen-specific immunotherapy
  • Report on mechanisms of immunotherapy with antigen processing independent T cell epitopes (apitopes), describing recent clinical trials of the approach for immunotherapy of autoimmune diseases
  • Explore the potential for combination approaches to promote antigen-specific immunotherapy

9:30 am From Bench to Bedside: Pre-Clinical & Clinical Results of Tolerogenic Therapy of Celiac Disease using Gliadin-Encapsulating PLG Nanoparticles

  • Stephen Miller Co-Founder of Cour Pharmaceuticals; Professor of Microbiology- Immunology, Northwestern University Medical School

Synopsis

  • Tolerance induction using antigen-encapsulating PLG nanoparticles (Ag-PLG) recapitulates how self-tolerance is induced and maintained in the hematopoietic system
  • Ag-PLG uptake by splenic marginal zone and liver APCs confers atolerogenic phenotype
  • Ag-PLG induces the induction of CD4+Foxp3+, CD4+ Tr1, and CD8+CD122+ regulatory T cells

10:00 am Speed Networking

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the Antigen-Specific Immune Tolerance field and establish meaningful business relationships to pursue for the rest of the conference.

10:30 am Morning Break & Refreshments

11:00 am From Mechanism to Clinical Trial – Blocking Disease-Specific HLA in Type 1 Diabetes

  • Aaron Michels Associate Professor of Pediatrics Medicine, & Immunology, Barbara Davis Center for Diabetes, University of Colorado; Chief Scientific Officer, IM Therapeutics

Synopsis

  • The HLA-DQ8 gene confers significant risk for developing type 1 diabetes and is present in 50-60% of all patients
  • The HLA-DQ8 molecule is remarkably amenable to binding small molecules within pockets in the peptide-binding groove
  • A clinically well-established small molecule drug, Methyldopa, blocks DQ8
    binding to disease-specific antigens in type 1 diabetes

11:30 am Mitigation of Anti-Drug Antibodies with ImmTOR Tolerogenic Nanoparticles

Synopsis

  • Pre-clinical development of ImmTOR
  • SEL-212 Phase 2 clinical proof-of-concept with a pegylated uricase enzyme
  • Application to gene therapy

12:00 pm Lunch & Networking

Optimizing the Identification of Novel Targets: Evaluation of Antigen & Epitope Discovery

1:00 pm Antigen Discovery for Tolerance Induction (Using Immunoinformatics)

  • Anne De Groot Founder, Chief Executive Officer & Chief Scientific Officer, Epivax

Synopsis

  • Tolerance induction requires antigen specificity – for some diseases, antigens are unknown
  • T cell epitopes are critical to both immunogenicity and tolerance in antigenspecifictolerance induction
  • Immunoinformatics tools can be used to screen antigen targets; their Treg epitope and T effector epitope content can be measured in silicon and validated in vitro and in vivo
  • Case studies of autoimmune disease antigens that have been discovered and evaluated using Immunoinformatics tools will be discussed

1:30 pm Antigen Discovery as Key Prerequisite for Successful Tolerization & Vaccination Strategies in Autoimmune Diseases, Allergies & Oncology

  • Martin Roland Head - Department of Neuroimmunology & Multiple Sclerosis Research, University Hospital Zurich

Synopsis

  • Challenges of antigen discovery in the autoimmune disease and tumor immunology field
  • Comparison of antigen discovery strategies
  • Presentation and discussion of our own approach with several proof-of-principle
    examples

Tolerance Delivery Systems & Trial Design Optimization

2:00 pm The Importance of Tolerance Delivery Systems in Antigen-Specific Immune Tolerance

Synopsis

  • Importance of tolerance delivery systems
  • ADi’s design philosophy and approach as a model for tolerance delivery: challenges and possibilities
  • Translation of ADi from animal models to the clinic

2:30 pm Afternoon Break & Refreshments

3:00 pm A Review of Clinically Tested ASIT Delivery Systems & Implications for Future Design

  • Cory Berkland Cory Berkland Distinguished Professor, School of Pharmacy Pharmaceutical Chemistry, University of Kansas

Synopsis

  • Explore clinical formulations and delivery of ASIT
  • Immune mechanisms relating to the delivery and physicochemical properties of ASIT
  • Design of delivery systems for ASIT to engage particular immune pathways

3:30 pm Induction of Antigen-specific TR1 Cells & Therapeutic Outcomes in Autoimmune Models Using Navacim™ Precision Nanomedicines

  • Curtis Ruegg President & Chief Executive Officer, Parvus Therapeutics, Inc.

Synopsis

  • Direct evidence for induction of antigen-specific type 1 T regulatory cells
  • The nanoparticle component is more than just a delivery system
  • Navacim-induced antigen-specific TR1 cells induce therapeutic bystander suppression

4:00 pm Novel Approaches to Antigen Delivery & Immune Response Monitoring

  • Colin Dayan Professor of Clinical Diabetes & Metabolism, Cardiff University School of Medicine

Synopsis

  • Antigen specific immunotherapy with gold nanoparticles
  • Flow cytometry of lymph nodes in new-onset type 1 diabetes
  • Single cell analysis of skin blisters and draining lymph nodes following antigen specific immunotherapy

4:30 pm Chair’s Closing Remarks

4:40 pm Sentific Poster Session